Pharma IQ Members

Assay Development

Assay Development is a procedure in molecular biology for testing or measuring the activity of a drug or biochemical in an organism or organic sample. A quantitative assay may also measure the amount of a substance in a sample. Bioassays and immunoassays are among the many varieties of specialized biochemical assays. Other assays measure processes such as enzyme activity, antigen capture, stem cell activity, and competitive protein binding.

Gerald Clarke

Why are NASA using human stem cells to study the chicken pox virus? How could this help astronauts in space?  How is the Mars Rover mission helping?  And why are the Russians so interested?  Find out with Thomas J. Goodwin, Manager, Disease...

Contributor: Gerald Clarke
11/04/2013 07:00:00 PM EST
The pre-clinical phase of drug discovery  involves many years of research being conducted by multi-disciplinary teams. These teams will generate significant amounts of data which are processed using standard as well as specialist software.  ...
Contributor: Sheraz Gul
08/28/2012 08:00:00 PM EDT
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing

This video presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes: • are a valid model of cardiomyocytes from the...

04/18/2012 08:00:00 PM EDT
Andrea Charles

In this podcast Mark Hembarsky, Vice President and Site Leader of the Aptuit Medicines Research Centre in Verona, Italy, and his colleagues Mauro Corsi, Head of Assay Development and In Vitro Profiling Preclinical Technologies, Sergio Raimondo,...

Contributor: Andrea Charles
09/07/2011 08:00:00 PM EDT
Andrea Charles

The lengthy clinical development process of drug development for life threatening diseases is not an optimal development strategy for oncology therapeutic area. Adaptive designs have become popular tools in oncology research, helping to achieve...

Contributor: Andrea Charles
06/06/2011 08:00:00 PM EDT
Pharma IQ News

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's Immunogenicity event to discuss FDA directives on Immunogenicity introduced in 2008.  Over the last...

Contributor: Pharma IQ News
04/03/2011 08:00:00 PM EDT
Andrea Charles

As part of the Pharma Leaders Today Series Dr. Keith Horspool, Vice President, Pharmaceutical Development US, Boehringer Ingelheim, speaks to Andrea Charles from Pharma IQ, about why changes are needed to current preformulation and formulation...

Contributor: Andrea Charles
03/14/2011 08:00:00 PM EDT
Assay Development and Immunogenicity Testing

Immunogenicity is becoming an integral feature within drug development activities. Testing immunogenicity, however, presents those within the pharmaceutical industry with a host of challenges; ones which must be overcome as developers look to...

Contributor: Pharma IQ
02/24/2011 07:00:00 PM EST
The Process of Drug Development: Time to Market

The term Drug Development covers a wide range of activities, from clinical trials to the creation of new compounds, all of which help drive a particular product to market. In its entirety, the process can take more than a decade, and cost...

Contributor: Pharma IQ
11/09/2010 07:00:00 PM EST
Pharma IQ

Dr. Timothy Robison, Pharmacology/Toxicology Reviewer at the US Food and Drug Administration/CDER, joins Helen Winsor from Pharma IQ, to share the latest insights into achieving successful characterisation of genotoxic impurities and accurate...

Contributor: Pharma IQ
09/21/2010 08:00:00 PM EDT
Helen Winsor

Reto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best practice tips for assessing and working with a CRO...

Contributor: Helen Winsor
09/07/2010 08:00:00 PM EDT
Pharma IQ

Reto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker development at the moment and discusses some key...

Contributor: Pharma IQ
09/05/2010 08:00:00 PM EDT
Immunogenicity- IQPC

The FDA has confirmed it will be providing a presentation on the FDA Guidance for Industry White Paper: Ensuring Compliance in Assay Development Immunogenicity Testing. Dr Jennifer Reed, Team Leader, CBER FDA, will be delivering the information...

Contributor: Immunogenicity- IQPC
05/26/2010 08:00:00 PM EDT
Pharma IQ

When it comes to drug development, immunogenicity is one concept that has risen up the agenda for pharmaceutical companies in the past few years. Much investment has been placed into improving the potential for a drug to trigger a person's immune...

Contributor: Pharma IQ
05/11/2010 08:00:00 PM EDT